Noroviruses are pernicious intestinal viruses. They cause violent vomiting and diarrhea, and people ill with the virus remain contagious up to three days after they seem to recover.
Although a vaccine for these viruses is in clinical trials, there is still no medication to combat them. That’s in part because researchers have not been able to culture human noroviruses so they can test potential treatments — until now, according to a study by University of Florida Health researchers published Friday, Nov. 7 in the journal Science.
UF Health researchers Stephanie Karst, Ph.D. (right), and Melissa Jones, Ph.D., have discovered how to grow the norovirus in human cells, opening the way to develop antivirals and vaccines.
UF Health researcher Stephanie Karst, Ph.D., has found a way to grow a human norovirus by identifying a cell it targets in the intestine.
“The biggest hurdle to doing norovirus research for its entire history — it was discovered in 1972 — has been that we can’t culture the human viruses in a cell culture dish,” said Karst, an associate professor in the department of molecular genetics and microbiology in the UF College of Medicine. “That complicates every aspect of research. We can’t study how it replicates, we can’t test therapeutics and we can’t generate live virus vaccines.”
According to the Centers for Disease Control and Prevention, in the United States, human noroviruses cause 19 to 21 million cases of illness per year, and contribute to 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly in young children and older adults. Noroviruses are resistant to many common disinfectants. Very little of the virus is needed to infect a host, so a surface may still contain enough virus to infect a person even after it is cleaned.
Previously, researchers speculated that noroviruses primarily target intestinal epithelial cells, which line the intestine and protect it from pathogens, Karst said. However, this new research demonstrates that the virus targets B cells, a type of white blood cell common in the intestine.
“That’s a big surprise,” Karst said. “You would think that any virus that’s going to target the intestine would instead target the intestinal epithelial cells because that’s the first cell the virus is going to encounter.”
Researchers also were surprised to find that bacteria present in the body’s gut flora, also known as commensal bacteria, helped the human norovirus infect B cells. Karst said scientists have long known that noroviruses need a particular kind of carbohydrate to infect cells.
“What we’ve shown is that noroviruses attach to that carbohydrate expressed on commensal bacteria, and that this interaction stimulates viral infection of the B cell,” Karst said. “This is a really exciting, emerging theme. A variety of intestinal viruses seem to exploit the bacteria that are present in our intestines all the time. These viral infections are enhanced by the presence of bacteria in the gut.”
UF research scientist Melissa Jones, Ph.D., a co-author on the paper, said the idea to study B cells came from Karst’s research on mouse noroviruses. UF scientists detected virus in Peyer’s patches, pockets of lymphoid nodules that line the intestine and survey the organ for pathogens.
This system can now be used to study norovirus replication and assess effectiveness of therapeutics and disinfectants, though more work needs to be done to increase its efficiency. Karst and Jones said while this is the first time researchers have been able to culture a human norovirus, the virus does not replicate to high levels in the current system, which hinders growth of the virus in the laboratory.
“Ultimately, this system should open up new avenues for norovirus vaccine and antiviral drug development,” Karst said.
Morgan Sherburne | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences